mk-2206 mk-2206 mk-2206 is a drug candidate being investigated to help treat cancer. its chemical formula is c25h21n5o. it acts as an allosteric akt inhibitor. mk-2206 names preferred iupac name 8--9-phenyltriazolo naphthyridin-3(2h)-one identifiers cas number 1032349-93-1 y 3d model (jsmol) interactive image chebi chebi:67271 chembl chembl1079175 chemspider 24658140 echa infocard 100.207.435 ec number 682-246-4 pubchem cid 24964624 unii 51hzg6mp1k comptox dashboard (epa) dtxsid3048948 inchi inchi=1s/c25h21n5o/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15h,4,12-13,26h2,(h,29,31)key: uldxwlcxedxjge-uhfffaoysa-ninchi=1/c25h21n5o/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15h,4,12-13,26h2,(h,29,31)key: uldxwlcxedxjge-uhfffaoyax smiles c1cc(c1)(c2=cc=c(c=c2)c3=c(c=c4c(=n3)c=cn5c4=nnc5=o)c6=cc=cc=c6)n properties chemical formula c25h21n5o molar mass 407.477 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references it is a highly selective inhibitor of pan-akt, namely, of all three akt isoforms akt1, akt2, and akt3. it is intended to be used with other cancer therapies that advanced tumours may become resistant to. clinical trials 2011: a phase 1 clinical trial of mk-2206 alone has reported it was well tolerated. 2014: a phase 1 clinical trial of mk-2206 with a variety of other agents in 72 patients with advanced cancer reported acceptable side-effects. 2016: mk-2206 is one of the treatments in the i-spy2 adaptive clinical trial for breast cancer that had been selected for later stage trials. as of august 2017 31 phase ii clinical trials are registered, many completed. e.g. in colorectal cancer, breast cancer, and many others. mk-2206 and covid-19 data shown in a study preprint suggest that sars-cov-2 infection decreases cellular autophagy and that mk-2206, which induces autophagy, reduced virus replication by up to 88% in vitro. the study's authors propose that mk-2206 should be tested in clinical trials as a potential treatment for covid-19.